Myths vs facts: CYP2D6 and menopause

CYP2D6 is an enzyme that metabolizes many drugs, including some used during menopause (e.g., certain antidepressants for hot flashes or tamoxifen for breast cancer). A common myth is that CYP2D6 variants determine the timing or severity of menopause – there is no solid evidence for this. Another myth: a CYP2D6 genetic test can predict whether hormone replacement therapy will work. In fact, CYP2D6 does not directly metabolize estrogens. The fact is: CYP2D6 genotypes can influence the efficacy and side effects of certain medications taken during menopause (e.g., paroxetine, tamoxifen). However, clinical relevance is limited because many factors (liver function, other drugs) matter. A DTC test for CYP2D6 alone is not a medical tool and does not replace clinical advice. Evidence for a direct link between CYP2D6 and menopause is weak; pharmacogenetic evidence is moderate. Beware of exaggerated marketing claims.